To examine the effects of VEGF-A inhibition on the therapeutic potential of VEGFR2-targeted therapy, we used a mouse xenograft model inoculated with human gastric cancer cells according to previous preclinical evaluations of VEGFR2-targeted agents13, which were based on the evidence that there is minimal species-specificity in the effect of VEGF on VEGFR25. This evidence concerns the gene KDR and gastric cancer.